INCY vs VRTX
Incyte vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | INCY | VRTX |
|---|
| AI Score |
71
|
67
|
| Price |
$120.61
|
$496.21
|
| P/E Ratio |
14.83×
|
28.64×
|
| ROE |
24.9%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
86.0%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
53.3
|
66.6
|
| Beta |
0.758
|
0.292
|
| Expected Upside |
—
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for INCY versus VRTX.
INCY leads by 4 points.
INCY scores 71/100 (Buy) versus VRTX at 67/100 (Buy).
INCY Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical